1. Home
  2. CTW vs BDTX Comparison

CTW vs BDTX Comparison

Compare CTW & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTW

CTW Cayman Class A Ordinary Shares

N/A

Current Price

$2.47

Market Cap

171.6M

Sector

Technology

ML Signal

N/A

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$2.19

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTW
BDTX
Founded
2013
2014
Country
Japan
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.6M
171.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CTW
BDTX
Price
$2.47
$2.19
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$9.67
AVG Volume (30 Days)
28.9K
2.0M
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
130.71
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$1.93
52 Week High
$3.14
$4.94

Technical Indicators

Market Signals
Indicator
CTW
BDTX
Relative Strength Index (RSI) 47.27 39.16
Support Level $1.88 N/A
Resistance Level $2.68 $2.47
Average True Range (ATR) 0.23 0.32
MACD -0.07 -0.10
Stochastic Oscillator 37.97 0.28

Price Performance

Historical Comparison
CTW
BDTX

About CTW CTW Cayman Class A Ordinary Shares

CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: